Oruka Therapeutics, Inc.
ORKA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.19B
Close$
$0.99
98.3% downside
Current Fair Value
98.3% downsideOvervalued by 98.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.19 Billion |
|---|---|
| Enterprise Value | $2.14 Billion |
| Dividend Yield | $19.36 (-) |
| Earnings per Share | $-2.31 |
| Beta | -0.25 |
| Outstanding Shares | 55,172,410 |
Return
| Return on Equity | -23.89% |
|---|---|
| Return on Assets | -23.04% |
| Return on Invested Capital | -27.35% |
Valuation & Multiples
| P/E Ratio | -27.78 |
|---|---|
| PEG | -53.9 |
| Price to Sales | - |
| Price to Book Ratio | 7.15 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -16.07 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.1287▲ 127.41% |
|---|---|
| Total Calls | 40,400▲ 134.88% |
| Total Puts | 86,000▲ 485.03% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 114.04%▼ 5.90% |
|---|---|
| Total Invested | $2.55B▲ 59.21% |
| Investors Holding | 187▲ 42.00% |
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.